GlassScriptPhysician profile
Ekta Kadakia
NPI 1366189789
$794.23
in general payments reported to CMS, 2019-2025
11 companies · $794 in 2025
The $794 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.25 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $225.65 | 2025 | |
| Incyte Corporation | $156.74 | 2025 | Zynyz, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $137.53 | 2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $92.24 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Agios Pharmaceuticals, INC. | $37.14 | 2025 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $37.00 | 2025 | Enhertu, Lynparza |
| Emd Serono, INC. | $30.73 | 2025 | |
| Caris Mpi, INC. | $24.05 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $18.54 | 2025 | Epkinly |
| Eisai INC. | $17.65 | 2025 | |
| Geron Corporation | $16.96 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekta Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.